Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: A randomized trial

Alison J. Huang, Rachel Hess, Lily A. Arya, Holly E. Richter, Leslee L. Subak, Catherine S. Bradley, Rebecca G. Rogers, Deborah L. Myers, Karen C. Johnson, W. Thomas Gregory, Stephen R Kraus, Michael Schembri, Jeanette S. Brown

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. Study Design: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. Results: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤.001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of <250 mL after treatment. Conclusion: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume206
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Urinary Incontinence
Residual Volume
Therapeutics
Placebos
Urinary Retention

Keywords

  • antimuscarinic therapy
  • diagnostic algorithm
  • fesoterodine
  • urgency incontinence

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm : A randomized trial. / Huang, Alison J.; Hess, Rachel; Arya, Lily A.; Richter, Holly E.; Subak, Leslee L.; Bradley, Catherine S.; Rogers, Rebecca G.; Myers, Deborah L.; Johnson, Karen C.; Gregory, W. Thomas; Kraus, Stephen R; Schembri, Michael; Brown, Jeanette S.

In: American Journal of Obstetrics and Gynecology, Vol. 206, No. 5, 05.2012.

Research output: Contribution to journalArticle

Huang, AJ, Hess, R, Arya, LA, Richter, HE, Subak, LL, Bradley, CS, Rogers, RG, Myers, DL, Johnson, KC, Gregory, WT, Kraus, SR, Schembri, M & Brown, JS 2012, 'Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: A randomized trial', American Journal of Obstetrics and Gynecology, vol. 206, no. 5. https://doi.org/10.1016/j.ajog.2012.03.002
Huang, Alison J. ; Hess, Rachel ; Arya, Lily A. ; Richter, Holly E. ; Subak, Leslee L. ; Bradley, Catherine S. ; Rogers, Rebecca G. ; Myers, Deborah L. ; Johnson, Karen C. ; Gregory, W. Thomas ; Kraus, Stephen R ; Schembri, Michael ; Brown, Jeanette S. / Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm : A randomized trial. In: American Journal of Obstetrics and Gynecology. 2012 ; Vol. 206, No. 5.
@article{f76dddb5ea3444e7bbfde493063a2d04,
title = "Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: A randomized trial",
abstract = "Objective: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. Study Design: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. Results: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤.001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of <250 mL after treatment. Conclusion: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.",
keywords = "antimuscarinic therapy, diagnostic algorithm, fesoterodine, urgency incontinence",
author = "Huang, {Alison J.} and Rachel Hess and Arya, {Lily A.} and Richter, {Holly E.} and Subak, {Leslee L.} and Bradley, {Catherine S.} and Rogers, {Rebecca G.} and Myers, {Deborah L.} and Johnson, {Karen C.} and Gregory, {W. Thomas} and Kraus, {Stephen R} and Michael Schembri and Brown, {Jeanette S.}",
year = "2012",
month = "5",
doi = "10.1016/j.ajog.2012.03.002",
language = "English (US)",
volume = "206",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm

T2 - A randomized trial

AU - Huang, Alison J.

AU - Hess, Rachel

AU - Arya, Lily A.

AU - Richter, Holly E.

AU - Subak, Leslee L.

AU - Bradley, Catherine S.

AU - Rogers, Rebecca G.

AU - Myers, Deborah L.

AU - Johnson, Karen C.

AU - Gregory, W. Thomas

AU - Kraus, Stephen R

AU - Schembri, Michael

AU - Brown, Jeanette S.

PY - 2012/5

Y1 - 2012/5

N2 - Objective: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. Study Design: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. Results: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤.001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of <250 mL after treatment. Conclusion: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.

AB - Objective: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. Study Design: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. Results: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤.001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of <250 mL after treatment. Conclusion: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.

KW - antimuscarinic therapy

KW - diagnostic algorithm

KW - fesoterodine

KW - urgency incontinence

UR - http://www.scopus.com/inward/record.url?scp=84860273398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860273398&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2012.03.002

DO - 10.1016/j.ajog.2012.03.002

M3 - Article

C2 - 22542122

AN - SCOPUS:84860273398

VL - 206

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -